Alfons A den Broeder

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.6K citations · Full text

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.

Alfons A den Broeder, M.C.W. Creemers, Jaap Fransen et al. · PubMed · 2007 · 280 citations

Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis

Elke Arts, Călin D. Popa, Alfons A den Broeder et al. · Annals of the Rheumatic Diseases · 2014 · 273 citations

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

Alfons A den Broeder, Leo van de Putte, Rolf Rau et al. · PubMed · 2002 · 195 citations